Investors

MolMed at ASCO 2015 with three studies on the progress of NGR-hTNF therapy in mesothelioma Pdf
MolMed at ASCO 2015 with three studies on the progress of NGR-hTNF therapy in mesothelioma Pdf ▾

Investors

The Board of Directors approves draft financial statements for 2014 and calls for the General Meeting on 3 June 2015
The Board of Directors approves draft financial statements for 2014 and calls for the General Meeting on 3 June 2015 ▾

Investors

MolMed expands its pipeline by entering the CAR-T field having exercised the option right on San Raffaele Hospital CAR-CD44v6 project
MolMed expands its pipeline by entering the CAR-T field having exercised the option right on San Raffaele Hospital CAR-CD44v6 project ▾

Investors

Share capital increase successfully completed and fully subscribed for an amount equal to Euro 49,824,834.53
Share capital increase successfully completed and fully subscribed for an amount equal to Euro 49,824,834.53 ▾

Investors

End of offering period of the share capital increase, 99.24% subscribed for a total amount of Euro 49.4 million
End of offering period of the share capital increase, 99.24% subscribed for a total amount of Euro 49.4 million ▾

Investors

Consob approves the Supplement to the Registration Document, the Information Note and the Summary Note relating to the Share Capital Increase
Consob approves the Supplement to the Registration Document, the Information Note and the Summary Note relating to the Share Capital Increase ▾
Subscribe to